Q2 Earnings Forecast for NTLA Issued By William Blair

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at William Blair issued their Q2 2026 earnings estimates for Intellia Therapeutics in a research report issued on Wednesday, March 26th. William Blair analyst M. Minter forecasts that the company will post earnings per share of ($1.22) for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

A number of other research analysts have also issued reports on NTLA. Wedbush reiterated a “neutral” rating and issued a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Oppenheimer dropped their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. BMO Capital Markets lowered their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Chardan Capital decreased their price objective on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Finally, Barclays lowered their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $8.40 on Friday. The company has a market cap of $869.54 million, a P/E ratio of -1.54 and a beta of 1.97. The stock has a 50-day moving average of $10.01 and a two-hundred day moving average of $13.90. Intellia Therapeutics has a 1-year low of $8.11 and a 1-year high of $28.23.

Insiders Place Their Bets

In related news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 29,000 shares of company stock valued at $352,551 in the last quarter. 3.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $25,000. Sterling Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after purchasing an additional 2,867 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in Intellia Therapeutics during the fourth quarter valued at about $40,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics during the fourth quarter worth about $43,000. Finally, Jones Financial Companies Lllp raised its holdings in shares of Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.